Au congrès 2026 de la Société européenne d'oncologie médicale (ESMO), Hengrui Pharma présentera en avant-première 64 résultats de recherche portant sur son portefeuille innovant en oncologie

The article snippet reports 64 accepted results, including three article presentations and three rapid oral communications, across more than 10 areas of oncology and supportive care. It says more than 10 studies highlight the efficacy of HER2-targeting antibody-drug conjugates; the text is truncated before further details are provided.